• The document contains the transcript of the Q2 and H1 FY27 Earnings Conference Call for QMS Medical Allied Services Limited, held on November 17, 2026.
  • The event was an earnings call to discuss operating and financial highlights for the quarter and half year ended September 30, 2026.
  • Management participants included Mr. Mahesh Makhija (Chairman and Managing Director) and Mr. Mohit Tamhankar (Director, Compliance).
  • The transcript was made available on the company's website at https://qmsmas.com/ and filed with the stock exchange on November 21, 2026, signed by Company Secretary and Compliance Officer Toral Jailesh Bhadra.

Financial Highlights Disclosed:

  • Q2 FY27 Revenue from Operations: INR 52.5 crores (up 17.5% YoY from INR 44.7 crores in Q2 FY26)
  • H1 FY27 Revenue from Operations: INR 109.4 crores (up 20% YoY from INR 91.2 crores in H1 FY26)
  • Q2 FY27 EBITDA: INR 6.5 crores (EBITDA margin 12.4%) compared to INR 6.9 crores in Q2 FY26
  • H1 FY27 EBITDA: INR 14.8 crores (up 11% YoY from INR 13.4 crores in H1 FY26) with EBITDA margin of 13.6%
  • Q2 FY27 PAT: INR 2.4 crores (PAT margin 4.6%) compared to INR 3.6 crores in Q2 FY26
  • H1 FY27 PAT: INR 6.4 crores (PAT margin 5.8%) compared to INR 6.7 crores in H1 FY26
  • Employee expenses increased to INR 12.6 crores in Q2 FY27 from INR 3 crores in Q2 FY26 due to expansion investments

Strategic Business Updates:

  • The company is pursuing a two-vertical strategy: QMS Services (patient support programs) and QMS Products (medical device distribution and manufacturing)
  • Completed acquisition of remaining 24% stake in Saarathi Healthcare in September 2026, making it a wholly owned subsidiary
  • Announced composite scheme of arrangement to merge HCAH's patient support program business with Saarathi Healthcare through all-share swap (approximately 1.32 crore shares to be issued)
  • The combined service business is envisaged to be separately listed on NSE, subject to regulatory approvals
  • Combined platform will have 160+ active patient support programs, impacted 1.2+ million patients, and 2,000+ healthcare professionals across 35+ cities
  • Combined service business reported revenue of ~INR 109 crores in FY26 with target of ~INR 180 crores for FY27
  • Signed 5-year exclusive agreement with HEINE Opto for marketing and distribution of primary diagnostic instruments in India from January 1, 2027
  • HEINE generated approximately INR 30 crores revenue from India in 2026
  • Signed binding MOU to acquire 100% of BeamOptics Scientific, a technology company specializing in optical systems and IVD instruments with 7 patents filed

Segmental Revenue Breakdown (H1 FY27):

  • Products Division: INR 61 crores
  • Services Division: INR 48 crores
  • Point-of-care division: INR 15.5 crores (half yearly)
  • Patient service programs and educational B2B: ~INR 37 crores
  • Q-Devices revenue: ~INR 4.5 crores (first half)

Guidance and Outlook:

  • Service business targeting 20-25% CAGR growth
  • Full-year FY27 revenue guidance: INR 210-220 crores
  • Regulatory approvals for HCAH-Saarathi merger expected in 12-13 months
  • BeamOptics acquisition valuation to be determined post corporate action completion

Additional Notes Section

  • The document includes the complete transcript of the earnings conference call with Q&A session.
  • The company indicated that some statements made during the call were forward-looking and involved risks and uncertainties.
  • No unattached documents or presentations were mentioned in this filing.
  • The transcript contains detailed financial data and strategic updates as presented during the earnings call.